1 / 35

TOC - Global Molecular Diagnostics Market

The global molecular diagnostics market is predicted to grow from $10,914.6 million in 2020 to $24,228.0 million in 2031 and is expected to grow with a CAGR of 7.38% during the forecast period 2021-2031.<br>

bisreports
Download Presentation

TOC - Global Molecular Diagnostics Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Molecular Diagnostics Market - A Global and Regional Analysis Table of Content https://www.freepik.com/premium-photo/close-up-view-96-well-plate-used-biology- Global Molecular Diagnostics Market Focus on Product, Testing Location, Application, Technology, and End User Analysis and Forecast: 2021-2031 November 2021 1 All rights reserved at BIS Research Inc.

  2. BIS Research is a leading market intelligence and technology research company. BIS Research publishes in- depth market intelligence reports focusing on the market estimations, technology analysis, emerging high- growth applications, deeply segmented granular country-level market data and other important market parameters useful in the strategic decision making for senior management. BIS Research provides multi-client reports, company profiles, databases, and custom research services. Global Molecular Diagnostics Market Copyright © 2021 BIS Research Inc. All Rights Reserved. This document contains highly confidential information and is the sole property of BIS Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third party. 2 All rights reserved at BIS Research Inc.

  3. Table of Content Executive Summary .......................................................................... 36 Research Methodology ..................................................................... 45 Scope of the Study ........................................................................... 50 1.Markets ..................................................................................... 53 1.1 Product Definition ............................................................................................ 54 1.1.1Definitions .................................................................................................... 54 1.1.2Inclusion and Exclusion ............................................................................. 55 1.2 Market Overview .............................................................................................. 55 1.3 Historical Perspective ..................................................................................... 57 1.4 Significant Technologies ................................................................................ 58 1.5 Classification of Molecular Diagnostics ........................................................ 59 1.6 Global Footprint ............................................................................................... 61 1.7 Global Molecular Diagnostics Market Size and Forecast - Realistic, Optimistic, and Conservative Growth Scenario ............................................ 62 1.7.1Realistic Growth Scenario .......................................................................... 62 1.7.2Conservative Growth Scenario .................................................................. 63 1.8 Future Potential ............................................................................................... 63 1.8.1Optimistic Growth Scenario ....................................................................... 64 1.9 Market Dynamics ............................................................................................. 65 1.9.1Impact Analysis ........................................................................................... 66 Global Molecular Diagnostics Market 1.9.2Market Drivers ............................................................................................. 66 1.9.2.1 A Highly Increasing Prevalence of Infectious Diseases and Various Types of Cancer, Globally ............................................................................................ 66 1.9.2.2 Growth in the Biomarker Identification Market and Advancements in Molecular Techniques ........................................................................................ 68 1.9.2.3 Increase in Awareness and Acceptance of Personalized Medicines on a Global Level ....................................................................................................... 69 3 All rights reserved at BIS Research Inc.

  4. 1.9.2.4 Significant External Funding for Executing Research and Development Exercises ........................................................................................................... 70 1.9.3Market Restraints ........................................................................................ 70 1.9.3.1 Uncertain Reimbursement Scenario .................................................................. 70 1.9.3.2 Lack of High-Complexity Testing Centers ......................................................... 71 1.9.3.3 Complex Regulatory Frameworks Delaying the Approval of New Molecular Diagnostic Tests ................................................................................................ 71 1.9.4Market Opportunities .................................................................................. 72 1.9.4.1 Massive Scope for Adoption of Molecular Diagnostics in Emerging Nations ........................................................................................................................... 72 1.9.4.2 Rise of Next-Generation Ultrasensitive Molecular Diagnostics ......................... 73 1.9.4.3 Novel Revenue Streams .................................................................................... 73 1.10COVID-19 Impact on Global Molecular Diagnostics Market ......................... 74 1.10.1Impact on Market Size ................................................................................. 75 1.10.2Impact on Molecular Diagnostic Practices ................................................ 76 1.11Competitive Landscape................................................................................... 76 1.11.1Acquisitions ................................................................................................. 77 1.11.2Synergistic Activities .................................................................................. 78 1.11.3Product Launches and Upgradations ........................................................ 79 1.11.4Business Expansion ................................................................................... 80 1.11.5Market Share Analysis, by Company ......................................................... 80 1.11.6Growth Share Analysis, by Technology .................................................... 82 1.12Industry Insights .............................................................................................. 83 Global Molecular Diagnostics Market 1.12.1Legal Requirements and Framework in the U.S. ...................................... 83 1.12.2FDA Regulations .......................................................................................... 84 1.12.3Legal Requirements and Framework in Europe ....................................... 84 1.12.3.1 U.K. .................................................................................................................... 84 1.12.3.2 Germany ............................................................................................................ 84 1.12.4Legal Requirements and Framework in Asia-Pacific ............................... 84 1.12.4.1 China ................................................................................................................. 84 4 All rights reserved at BIS Research Inc.

  5. 1.12.4.2 Japan ................................................................................................................. 86 1.12.4.2.1Pharmaceuticals and Medical Devices Agency (PMDA) ......................................... 86 1.12.4.2.2Ministry of Health, Labour, and Welfare (MHLW) .................................................... 87 1.12.4.3 India ................................................................................................................... 87 1.13Patent Analysis ................................................................................................ 87 1.13.1Patent Filing Trend ...................................................................................... 87 2.Products .................................................................................... 89 2.1 Overview ........................................................................................................... 90 2.1.1Systems ........................................................................................................ 91 2.1.2Kits and Consumables ................................................................................ 94 2.1.3Software and Other Products ..................................................................... 97 3.Testing Location ...................................................................... 101 3.1 Overview ......................................................................................................... 102 3.1.1Laboratory Testing .................................................................................... 103 3.1.2Point-of-Care Testing ................................................................................ 104 4. Technology ............................................................................. 106 4.1 Overview ......................................................................................................... 107 4.1.1Polymerase Chain Reaction (PCR) .......................................................... 108 4.1.2Next-Generation Sequencing ................................................................... 112 4.1.3Isothermal Nucleic Acid Amplification Technology (INAAT) ................. 113 4.1.4Microarray .................................................................................................. 116 4.1.5In-Situ Hybridization (ISH) ........................................................................ 119 Global Molecular Diagnostics Market 4.1.6Immunohistochemistry (IHC) ................................................................... 121 4.1.7Other Technologies ................................................................................... 123 5.Application .............................................................................. 126 5.1 Overview ......................................................................................................... 127 5.1.1Core Molecular Diagnostics ..................................................................... 128 5.1.1.1 Infectious Disease ........................................................................................... 130 5.1.1.1.1Respiratory Infections ............................................................................................ 134 5 All rights reserved at BIS Research Inc.

  6. 5.1.1.1.1.1Influenza A and B ........................................................................................... 138 5.1.1.1.1.2COVID-19 Infections ....................................................................................... 140 5.1.1.1.1.3Respiratory Syncytial Virus ............................................................................. 141 5.1.1.1.1.4Mycoplasma Infections ................................................................................... 142 5.1.1.1.1.5Pertussis ......................................................................................................... 144 5.1.1.1.1.6Other Respiratory Infections ........................................................................... 145 5.1.1.1.2Sexual Transmitted Infections(STI)........................................................................ 146 5.1.1.1.2.1Common Pathogens Associated with Sexually Transmitted Infection ........... 147 5.1.1.1.2.2Hepatitis B ...................................................................................................... 148 5.1.1.1.2.3HIV-AIDS ........................................................................................................ 149 5.1.1.1.2.4HPV ................................................................................................................. 151 5.1.1.1.2.5Herpes Simplex Virus ..................................................................................... 152 5.1.1.1.2.6Neisseria Gonorrhoeae ................................................................................... 154 5.1.1.1.2.7Other STIs ...................................................................................................... 155 5.1.1.2 Hereditary Genetic Testing .............................................................................. 156 5.1.1.3 Blood Donor Screening .................................................................................... 159 5.1.1.4 Oncology .......................................................................................................... 162 5.1.1.5 Human Leukocyte Antigen (HLA) Testing ....................................................... 166 5.1.1.6 Other Molecular Diagnostics Applications ....................................................... 168 5.1.2Reproductive Genetics ............................................................................. 169 5.1.2.1 Carrier Screening ............................................................................................. 171 5.1.2.2 Non-Invasive Pre-Natal Testing (NIPT) ........................................................... 173 5.1.2.3 Pre-Implantation Genetic Testing .................................................................... 175 Global Molecular Diagnostics Market 5.1.2.4 Infertility Genetic Testing ................................................................................. 176 5.1.3Companion Diagnostics (CDx) ................................................................. 178 5.1.4Liquid Biopsy ............................................................................................. 179 5.1.5Other Applications .................................................................................... 181 6. End-User ................................................................................. 183 6.1 Overview ......................................................................................................... 184 6.1.1Hospitals .................................................................................................... 185 6 All rights reserved at BIS Research Inc.

  7. 6.1.1.1 Hospitals, by Respiratory Infections Molecular Diagnostics Market ................ 187 6.1.1.1.1Hospitals, by Influenza A and B ............................................................................. 188 6.1.1.1.2Hospitals, by COVID-19 Infections ........................................................................ 189 6.1.1.1.3Hospitals, by Respiratory Syncytial Virus .............................................................. 191 6.1.1.1.4Hospitals, by Mycoplasma Infection....................................................................... 192 6.1.1.1.5Hospitals, by Pertussis ........................................................................................... 193 6.1.1.1.6Hospitals, by Other Respiratory Infections ............................................................ 195 6.1.1.2 Hospitals Sexually Transmitted Infections (STIs) Market ................................ 196 6.1.1.2.1Hospitals, by Hepatitis B ........................................................................................ 197 6.1.1.2.2Hospitals, by HIV AIDS .......................................................................................... 199 6.1.1.2.3Hospitals, by HPV .................................................................................................. 200 6.1.1.2.4Hospitals, by Herpes Simplex Virus(HSV) ............................................................. 201 6.1.1.2.5Hospitals, by Neisseria gonorrhoeae .................................................................... 202 6.1.1.2.6Hospitals, by Other STIs ........................................................................................ 203 6.1.2Diagnostic Centers .................................................................................... 204 6.1.2.1 Diagnostic Centers, by Respiratory Infections Molecular Diagnostics Market .............................................................................................................. 205 6.1.2.1.1Diagnostic Centers, by Influenza A and B ............................................................. 207 6.1.2.1.2Diagnostic Centers, by COVID-19 Infections ......................................................... 208 6.1.2.1.3Diagnostic Centers, by Respiratory Syncytial Virus ............................................... 209 6.1.2.1.4Diagnostic Centers, by Mycoplasma Infection ....................................................... 210 6.1.2.1.5Diagnostic Centers, by Pertussis ........................................................................... 211 6.1.2.1.6Diagnostic Centers, by Other Respiratory Infections ............................................. 212 Global Molecular Diagnostics Market 6.1.2.2 Diagnostic Centers Sexually Transmitted Infections (STIs) Market ................. 213 6.1.2.2.1Diagnostic Centers, by Hepatitis B ........................................................................ 214 6.1.2.2.2Diagnostic Centers, by HIV AIDS .......................................................................... 215 6.1.2.2.3Diagnostic Centers, by HPV .................................................................................. 216 6.1.2.2.4Diagnostic Centers, by Herpes Simplex Virus(HSV) ............................................. 217 6.1.2.2.5Diagnostic Centers, by Neisseria gonorrhoeae .................................................... 218 6.1.2.2.6Diagnostic Centers, by Other STIs ........................................................................ 219 7 All rights reserved at BIS Research Inc.

  8. 6.1.3Out-Patient Clinics/General Practitioners ............................................... 221 6.1.3.1 Out-Patient Clinics/General Practitioners, by Respiratory Infections Molecular Diagnostics Market .......................................................................... 222 6.1.3.1.1Out-Patient Clinics/General Practitioners, by Influenza A and B ........................... 224 6.1.3.1.2Out-Patient Clinics/General Practitioners, by COVID-19 Infections ...................... 225 6.1.3.1.3Out-Patient Clinics/General Practitioners, by Respiratory Syncytial Virus ............ 226 6.1.3.1.4Out-Patient Clinics/General Practitioners, by Mycoplasma Infection .................... 227 6.1.3.1.5Out-Patient Clinics/General Practitioners, by Pertussis ........................................ 228 6.1.3.1.6Out-Patient Clinics/General Practitioners, by Other Respiratory Infections .......... 229 6.1.3.2 Out-Patient Clinics/General Practitioners Sexually Transmitted Infections (STIs) Market ................................................................................................... 230 6.1.3.2.1Out-Patient Clinics/General Practitioners, by Hepatitis B ...................................... 231 6.1.3.2.2Out-Patient Clinics/General Practitioners, by HIV AIDS ........................................ 232 6.1.3.2.3Out-Patient Clinics/General Practitioners, by HPV ................................................ 233 6.1.3.2.4Out-Patient Clinics/General Practitioners, by Herpes Simplex Virus(HSV) ........... 234 6.1.3.2.5Out-Patient Clinics/General Practitioners, by Neisseria gonorrhoeae .................. 235 6.1.3.2.6Out-Patient Clinics/General Practitioners, by Other STIs ...................................... 236 6.1.4Research Laboratories .............................................................................. 238 6.1.4.1 Research Laboratories, by Respiratory Infections Molecular Diagnostics Market .............................................................................................................. 239 6.1.4.1.1Research Laboratories, by Influenza A and B ....................................................... 240 6.1.4.1.2Research Laboratories, by COVID-19 Infections ................................................... 241 6.1.4.1.3Research Laboratories, by Respiratory Syncytial Virus ........................................ 242 6.1.4.1.4Research Laboratories, by Mycoplasma Infection ................................................. 243 Global Molecular Diagnostics Market 6.1.4.1.5Research Laboratories, by Pertussis ..................................................................... 244 6.1.4.1.6Research Laboratories, by Other Respiratory Infections ....................................... 245 6.1.4.2 Research Laboratories Sexually Transmitted Infections (STIs) Market ........... 246 6.1.4.2.1Research Laboratories, by Hepatitis B .................................................................. 247 6.1.4.2.2Research Laboratories, by HIV AIDS .................................................................... 248 6.1.4.2.3Research Laboratories, by HPV ............................................................................ 249 8 All rights reserved at BIS Research Inc.

  9. 6.1.4.2.4Research Laboratories, by Herpes Simplex Virus(HSV) ....................................... 250 6.1.4.2.5Research Laboratories, by Neisseria gonorrhoeae .............................................. 251 6.1.4.2.6Research Laboratories, by Other STIs .................................................................. 252 6.1.5Other End Users ........................................................................................ 254 7. Regions................................................................................... 255 7.1 Overview ......................................................................................................... 256 7.2 North America ................................................................................................ 258 7.2.1North America Molecular Diagnostics Market (by Application) ............ 261 7.2.1.1 North America Respiratory Infections Molecular Diagnostics Market .............. 261 7.2.1.1.1North America, by Influenza A and B ..................................................................... 262 7.2.1.1.2North America, by COVID-19 Infections ................................................................ 263 7.2.1.1.3North America, by Respiratory Syncytial Virus ...................................................... 264 7.2.1.1.4North America, by Mycoplasma Infection .............................................................. 265 7.2.1.1.5North America, by Pertussis .................................................................................. 266 7.2.1.1.6North America, by Other Respiratory Infections .................................................... 267 7.2.1.2 North America Sexually Transmitted Infections (STIs) Market ........................ 268 7.2.1.2.1North America, by Hepatitis B ................................................................................ 270 7.2.1.2.2North America, by HIV AIDS .................................................................................. 271 7.2.1.2.3North America, by HPV .......................................................................................... 272 7.2.1.2.4North America, by Herpes Simplex Virus(HSV) ..................................................... 273 7.2.1.2.5North America, by Neisseria gonorrhoeae ............................................................ 274 7.2.1.2.6North America, by Other STIs ................................................................................ 275 Global Molecular Diagnostics Market 7.2.2North America Molecular Diagnostics Market (by End User) ................ 276 7.2.3U.S. ............................................................................................................. 277 7.2.4Canada ....................................................................................................... 278 7.3 Europe ............................................................................................................ 282 7.3.1Europe Molecular Diagnostics Market (by Application) ......................... 285 7.3.1.1 Europe Respiratory Infections Molecular Diagnostics Market ......................... 286 7.3.1.1.1Europe, by Influenza A and B ................................................................................ 287 9 All rights reserved at BIS Research Inc.

  10. 7.3.1.1.2Europe , by COVID-19 Infections ........................................................................... 288 7.3.1.1.3Europe, by Respiratory Syncytial Virus ................................................................. 289 7.3.1.1.4Europe, by Mycoplasma Infection .......................................................................... 290 7.3.1.1.5Europe, by Pertussis .............................................................................................. 291 7.3.1.1.6Europe, by Other Respiratory Infections ................................................................ 292 7.3.1.2 Europe Sexually Transmitted Infections (STIs) Market ................................... 293 7.3.1.2.1Europe, by Hepatitis B ........................................................................................... 294 7.3.1.2.2Europe, by HIV AIDS ............................................................................................. 295 7.3.1.2.3Europe, by HPV ..................................................................................................... 296 7.3.1.2.4Europe, by Herpes Simplex Virus (HSV) ............................................................... 297 7.3.1.2.5Europe, by Neisseria gonorrhoeae ........................................................................ 298 7.3.1.2.6Europe, by Other STIs ........................................................................................... 299 7.3.2Europe Molecular Diagnostics Market (by End User) ............................ 300 7.3.3Germany ..................................................................................................... 301 7.3.4U.K. ............................................................................................................. 304 7.3.5France ......................................................................................................... 306 7.3.6Italy ............................................................................................................. 307 7.3.7Spain ........................................................................................................... 309 7.3.8Rest-of-Europe........................................................................................... 311 7.4 Asia-Pacific (APAC) ....................................................................................... 314 7.4.1Asia-Pacific Molecular Diagnostics Market (by Application) ................. 317 7.4.1.1 Asia-Pacific Respiratory Infections Molecular Diagnostics Market .................. 318 7.4.1.1.1Asia-Pacific, by Influenza A and B ......................................................................... 319 Global Molecular Diagnostics Market 7.4.1.1.2Asia-Pacific , by COVID-19 Infections ................................................................... 320 7.4.1.1.3Asia-Pacific, by Respiratory Syncytial Virus .......................................................... 321 7.4.1.1.4Asia-Pacific, by Mycoplasma Infection .................................................................. 322 7.4.1.1.5Asia-Pacific, by Pertussis ....................................................................................... 323 7.4.1.1.6Asia-Pacific, by Other Respiratory Infections ........................................................ 324 7.4.1.2 Asia-Pacific Sexually Transmitted Infections (STIs) Market ............................ 325 7.4.1.2.1Asia-Pacific, by Hepatitis B .................................................................................... 326 10 All rights reserved at BIS Research Inc.

  11. 7.4.1.2.2Asia-Pacific, by HIV AIDS ...................................................................................... 327 7.4.1.2.3Asia-Pacific, by HPV .............................................................................................. 328 7.4.1.2.4Asia-Pacific, by Herpes Simplex Virus (HSV) ........................................................ 329 7.4.1.2.5Asia-Pacific, by Neisseria gonorrhoeae ................................................................. 330 7.4.1.2.6Asia-Pacific, by Other STIs .................................................................................... 331 7.4.2Asia-Pacific Molecular Diagnostics Market (by End User) .................... 332 7.4.3China .......................................................................................................... 334 7.4.4India ............................................................................................................ 336 7.4.5Japan .......................................................................................................... 338 7.4.6Australia ..................................................................................................... 340 7.4.7Singapore ................................................................................................... 342 7.4.8Rest-of-Asia-Pacific ................................................................................... 345 7.5 Latin America (LATAM) ................................................................................. 346 7.5.1Latin America Molecular Diagnostics Market (by Application) ............. 349 7.5.1.1 Latin America Respiratory Infections Molecular Diagnostics Market ............... 350 7.5.1.1.1Latin America, by Influenza A and B ...................................................................... 352 7.5.1.1.2Latin America, by COVID-19 Infections ................................................................. 353 7.5.1.1.3Latin America, by Respiratory Syncytial Virus ....................................................... 354 7.5.1.1.4Latin America, by Mycoplasma Infection ............................................................... 355 7.5.1.1.5Latin America, by Pertussis ................................................................................... 356 7.5.1.1.6Latin America, by Other Respiratory Infections ..................................................... 357 7.5.1.2 Latin America Sexually Transmitted Infections (STIs) Market ......................... 358 7.5.1.2.1Latin America, by Hepatitis B ................................................................................. 359 Global Molecular Diagnostics Market 7.5.1.2.2Latin America, by HIV AIDS ................................................................................... 360 7.5.1.2.3Latin America, by HPV ........................................................................................... 361 7.5.1.2.4Latin America, by Herpes Simplex Virus (HSV) ..................................................... 362 7.5.1.2.5Latin America, by Neisseria gonorrhoeae .............................................................. 363 7.5.1.2.6Latin America, by Other STIs ................................................................................. 364 7.5.2Latin America Molecular Diagnostics Market (by End User) ................. 365 7.5.3Brazil ........................................................................................................... 366 11 All rights reserved at BIS Research Inc.

  12. 7.5.4Mexico ........................................................................................................ 368 7.5.5Rest-of-Latin America ............................................................................... 369 7.6 Rest-of-the-World (RoW) ............................................................................... 371 7.6.1Rest-of-the-World Molecular Diagnostics Market (by Application) ....... 373 7.6.2Rest-of-the-World Molecular Diagnostics Market (by End User) ........... 374 7.6.2.1 Rest-of-the-World Respiratory Infections Molecular Diagnostics Market ........ 375 7.6.2.2 Rest-of-the-World Sexually Transmitted Infections (STIs) Market ................... 377 8.Company Profiles ..................................................................... 379 8.1 Overview ......................................................................................................... 380 8.2 Abbott ............................................................................................................. 381 8.2.1Company Overview ................................................................................... 381 8.2.2Role of Abbott in the Global Molecular Diagnostics Market .................. 381 8.2.3Financials ................................................................................................... 383 8.2.4Key Insights about Financial Health of the Company ............................ 385 8.2.5SWOT Analysis .......................................................................................... 386 8.3 Agilent Technologies, Inc. ............................................................................ 387 8.3.1Company Overview ................................................................................... 387 8.3.2Role of Agilent Technologies, Inc. in the Global Molecular Diagnostics Market .................................................................................... 387 8.3.3Financials ................................................................................................... 389 8.3.4Key Insights about Financial of the Company ........................................ 391 8.3.5SWOT Analysis .......................................................................................... 392 Global Molecular Diagnostics Market 8.4 Becton, Dickinson and Company (BD) ........................................................ 393 8.4.1Company Overview ................................................................................... 393 8.4.2Role of Becton, Dickinson and Company (BD) in the Global Molecular Diagnostics Market .................................................................. 393 8.4.3Financials ................................................................................................... 395 8.4.4Key Insights about Financial Health of the Company ............................ 397 8.4.5SWOT Analysis .......................................................................................... 398 12 All rights reserved at BIS Research Inc.

  13. 8.5 bioMérieux SA ................................................................................................ 399 8.5.1Company Overview ................................................................................... 399 8.5.2Role of bioMérieux SA in the Global Molecular Diagnostics Market .... 399 8.5.3Financials ................................................................................................... 401 8.5.4Key Insights about Financial Health of the Company ............................ 403 8.5.5SWOT Analysis .......................................................................................... 404 8.6 Bio-Rad Laboratories, Inc. ............................................................................ 405 8.6.1Company Overview ................................................................................... 405 8.6.2Role of Bio-Rad Laboratories, Inc. in the Global Molecular Diagnostics Market .................................................................................... 405 8.6.3Financials ................................................................................................... 407 8.6.4Key Insights about Financial Health of the Company ............................ 409 8.6.5SWOT Analysis .......................................................................................... 410 8.7 Danaher .......................................................................................................... 411 8.7.1Company Overview ................................................................................... 411 8.7.2Role of Danaher in the Global Molecular Diagnostics Market ............... 411 8.7.3Financials ................................................................................................... 413 8.7.4Key Insights about Financial Health of the Company ............................ 415 8.7.5SWOT Analysis .......................................................................................... 416 8.8 F. Hoffmann-La Roche Ltd ............................................................................ 417 8.8.1Company Overview ................................................................................... 417 8.8.2Role of F. Hoffmann-La Roche Ltd in the Global Molecular Diagnostics Market .................................................................................... 417 Global Molecular Diagnostics Market 8.8.3Financials ................................................................................................... 419 8.8.4Key Insights about Financial Health of the Company ............................ 421 8.8.5SWOT Analysis .......................................................................................... 422 8.9 Guardant Health ............................................................................................. 423 8.9.1Company Overview ................................................................................... 423 13 All rights reserved at BIS Research Inc.

  14. 8.9.2Role of Guardant Health in the Global Molecular Diagnostics Market .................................................................................................................... 423 8.9.3Financials ................................................................................................... 424 8.9.4Key Insights about Financial Health of the Company ............................ 426 8.9.5SWOT Analysis .......................................................................................... 427 8.10HTG Molecular Diagnostics, Inc. .................................................................. 428 8.10.1Company Overview ................................................................................... 428 8.10.2Role of HTG Molecular Diagnostics, Inc. in the Global Molecular Diagnostics Market .................................................................................... 428 8.10.3Financials ................................................................................................... 429 8.10.4Key Insights about Financial Health of the Company ............................ 431 8.10.5SWOT Analysis .......................................................................................... 432 8.11Illumina, Inc. ................................................................................................... 433 8.11.1Company Overview ................................................................................... 433 8.11.2Role of Illumina, Inc. in the Global Molecular Diagnostics Market ........ 433 8.11.3Financials ................................................................................................... 435 8.11.4Key Insights about Financial Health of the Company ............................ 437 8.11.5SWOT Analysis .......................................................................................... 438 8.12Invivoscribe, Inc. ............................................................................................ 439 8.12.1Company Overview ................................................................................... 439 8.12.2Role of Invivoscribe, Inc. in the Global Molecular Diagnostics Market ......................................................................................................... 439 8.12.3SWOT Analysis .......................................................................................... 440 Global Molecular Diagnostics Market 8.13ICON plc .......................................................................................................... 441 8.13.1Company Overview ................................................................................... 441 8.13.2Role of ICON plc in the Global Molecular Diagnostics Market .............. 441 8.13.3SWOT Analysis .......................................................................................... 442 8.14LungLife AI, Inc. ............................................................................................. 443 8.14.1Company Overview ................................................................................... 443 14 All rights reserved at BIS Research Inc.

  15. 8.14.2Role of LungLife AI, Inc. in the Global Molecular Diagnostics Market .................................................................................................................... 443 8.14.3SWOT Analysis .......................................................................................... 444 8.15QIAGEN........................................................................................................... 445 8.15.1Company Overview ................................................................................... 445 8.15.2Role of QIAGEN in the Global Molecular Diagnostics Market ............... 445 8.15.3Financials ................................................................................................... 447 8.15.4Key Insights about Financial Health of the Company ............................ 449 8.15.5SWOT Analysis .......................................................................................... 450 8.16QuantuMDx Group Ltd. ................................................................................. 451 8.16.1Company Overview ................................................................................... 451 8.16.2Role of QuantuMDx Group Ltd. in the Global Molecular Diagnostics Market ......................................................................................................... 451 8.16.3SWOT Analysis .......................................................................................... 453 8.17Siemens Healthcare GmbH ........................................................................... 454 8.17.1Company Overview ................................................................................... 454 8.17.2Role of Siemens Healthcare GmbH in the Global Molecular Diagnostics Market .................................................................................... 454 8.17.3Financials ................................................................................................... 456 8.17.4Key Insights about Financial Health of the Company ............................ 458 8.17.5SWOT Analysis .......................................................................................... 459 8.18Thermo Fisher Scientific Inc. ........................................................................ 460 8.18.1Company Overview ................................................................................... 460 Global Molecular Diagnostics Market 8.18.2Role of Thermo Fisher Scientific Inc. in the Global Molecular Diagnostics Market .................................................................................... 460 8.18.3Financials ................................................................................................... 462 8.18.4Key Insights About Financial Health of the Company ........................... 464 8.18.5SWOT Analysis .......................................................................................... 465 15 All rights reserved at BIS Research Inc.

  16. List of Figures Figure 1: Figure 2: Annual NIH Funding in Human Genomics Research, $Billion, FY2013-FY2019 Global Molecular Diagnostics Market (Realistic and Optimistic Scenario), $Million, 2020- 2031 Global Molecular Diagnostics Market, Market Dynamics Share of Key Market Strategies and Developments, January 2017-September 2021 Global Molecular Diagnostics Market Snapshot, $Million, 2020-2031 Global Molecular Diagnostics Market (by Product), $Million, 2020 Vs. 2031 Global Molecular Diagnostics Market (by Technology), $Million, 2020 Vs. 2031 Global Molecular Diagnostics Market (by Application), $Million, 2020 Vs. 2031 Global Molecular Diagnostics Market (by End User), $Million, 2020 Vs. 2031 Global Molecular Diagnostics Market (by Region), $Million, 2020 Vs. 2031 Global Molecular Diagnostics Market Research Methodology Global Molecular Diagnostics Market: Segmentation Figure 1.1: Role of Diagnostics in Healthcare Evolution of Molecular Diagnostics Classification of Molecular Diagnostics Global Molecular Diagnostics (MDx) Market, $Million, 2020-2031 Figure 3: Figure 4: Figure 5: Figure 6: Figure 7: Figure 8: Figure 9: Figure 10: Figure 11: Figure 12: Figure 13: Figure 14: Figure 15: Figure 16: Figure 17: Global Molecular Diagnostics Market Size and Growth Potential (Realistic Scenario), $Million, 2020-2031 Figure 18: Global Molecular Diagnostics Market Size and Growth Potential (Conservative Scenario), $Million, 2020-2031 Figure 19: Global Molecular Diagnostics Market Size and Growth Potential (Optimistic Scenario), $Million, 2020-2031 Global Molecular Diagnostics Market - Market Dynamics Distribution of Cases and Deaths by World Regions and Cancer Types Personalized Care for Cancer Patients Impact of COVID-19 on Global Molecular Diagnostics Market Share of Key Developments and Strategies, January 2017–September 2021 Share of Acquisitions (by Company), January 2017-September 2021 Share of Synergistic Activities (by Company), January 2017-September 2021 Figure 20: Figure 21: Figure 22: Figure 23: Figure 24: Figure 25: Figure 26: Figure 27: Global Molecular Diagnostics Market Share of Product Launches and Upgradations (by Company), January 2017–September 2021 Share of Business Expansion (by Company), July 2017-August 2021 Market Share Analysis for Global Molecular Diagnostics Market, $Million, 2019 and 2020 Figure 28: Figure 29: Figure 30: Growth Share Analysis of Global Molecular Diagnostics Market (by Technology), 2020- 2031 Responsibilities of the National Medical Products Administration (NMPA) Figure 31: Figure 32: Year-Wise Analysis of Patents Related to Molecular Diagnostics, January 2019- October 2021 16 All rights reserved at BIS Research Inc.

  17. Figure 33: Country-Wise Analysis (January 2019-October 2021) of Patents Related to Next- Generation Sequencing Share of Global Molecular Diagnostics Market (by Product), $Million, 2020 and 2031 Figure 34: Figure 35: Share of Global Molecular Diagnostics Market (by Product), Thousand Units, 2020 and 2031 Global Molecular Diagnostics Market (Systems), $Million, 2020-2031 Global Molecular Diagnostics Market (Systems), Thousand Units, 2020-2031 General Workflow of a Molecular Diagnostic Kit Global Molecular Diagnostics Market (Kits and Consumables), $Million, 2020-2031 Figure 36: Figure 37: Figure 38: Figure 39: Figure 40: Global Molecular Diagnostics Market (Kits and Consumables), Thousand Units, 2020- 2031 Aspects of Software Development Figure 41: Figure 42: Global Molecular Diagnostics Market (Software and Other Products), $Million, 2020- 2031 Figure 43: Global Molecular Diagnostics Market (Software and Other Products), Thousand Units, 2020-2031 Global Molecular Diagnostics Market (by Testing Location) Figure 44: Figure 45: Share of Global Molecular Diagnostics Market (by Testing Location), $Million, 2020 and 2031 Global Molecular Diagnostics Market (Laboratory Testing), $Million, 2020-2031 Global Molecular Diagnostics Market (Point-of-Care Testing), $Million, 2020-2031 Share of Global Molecular Diagnostics Market (by Technology), $Million, 2020 and 2031 Global Molecular Diagnostics Market (Polymerase Chain Reaction), $Million, 2020-2031 Figure 46: Figure 47: Figure 48: Figure 49: Figure 50: Global Molecular Diagnostics Market (Polymerase Chain Reaction), Thousand Units, 2020-2031 Figure 51: Global Molecular Diagnostics Market (Next-Generation Sequencing), $Million, 2020- 2031 Figure 52: Global Molecular Diagnostics Market (Next-Generation Sequencing), Thousand Units, 2020-2031 Figure 53: Global Molecular Diagnostics Market (Isothermal Nucleic Acid Amplification Technology), $Million, 2020-2031 Figure 54: Global Molecular Diagnostics Market (Isothermal Nucleic Acid Amplification Technology), Thousand Units, 2020-2031 Global Molecular Diagnostics Market (Microarray), $Million, 2020-2031 Global Molecular Diagnostics Market (Microarray), Thousand Units, 2020-2031 Global Molecular Diagnostics Market (ISH), $Million, 2020-2031 Global Molecular Diagnostics Market (ISH), Thousand Units, 2020-2031 Global Molecular Diagnostics Market (IHC), $Million, 2020-2031 Global Molecular Diagnostics Market (IHC), Thousand Units, 2020-2031 Global Molecular Diagnostics Market (Other Technologies), $Million, 2020-2031 Global Molecular Diagnostics Market (Other Technologies), Thousand Units, 2020-2031 Global Molecular Diagnostics Market (by Application), $Million, 2020 and 2031 Global Molecular Diagnostics Market (Core Molecular Diagnostics), $Million, 2020-2031 Figure 55: Figure 56: Figure 57: Figure 58: Figure 59: Figure 60: Figure 61: Figure 62: Figure 63: Figure 64: Global Molecular Diagnostics Market 17 All rights reserved at BIS Research Inc.

  18. Figure 65: Global Molecular Diagnostics Market (Core Molecular Diagnostics), Thousand Units, 2020-2031 Figure 66: Global Molecular Diagnostics Market (by Core Molecular Diagnostics), $Million, 2020 and 2031 Global Molecular Diagnostics Market (Infectious Disease), $Million, 2020-2031 Global Molecular Diagnostics Market (Infectious Disease), Thousand Units, 2020-2031 Global Molecular Diagnostics Market (by Infectious Disease), $Million, 2020-2031 Figure 67: Figure 68: Figure 69: Figure 70: Global Molecular Diagnostics Market (by Infectious Disease), Thousand Units, 2020- 2031 Global Molecular Diagnostics Market (Respiratory Infections), $Million, 2020-2031 Figure 71: Figure 72: Global Molecular Diagnostics Market (Respiratory Infections), Thousand Units, 2020- 2031 Global Molecular Diagnostics Market (Influenza A and B), $Million, 2020-2031 Global Molecular Diagnostics Market (Influenza A and B), Thousand Units, 2020-2031 Global Molecular Diagnostics Market (COVID-19 Infections), $Million, 2020-2031 Global Molecular Diagnostics Market (COVID-19 Infections), Thousand Units, 2020-2031 Global Molecular Diagnostics Market (Respiratory Syncytial Virus), $Million, 2020-2031 Figure 73: Figure 74: Figure 75: Figure 76: Figure 77: Figure 78: Global Molecular Diagnostics Market (Respiratory Syncytial Virus), Thousand Units, 2020-2031 Global Molecular Diagnostics Market (Mycoplasma Infections), $Million, 2020-2031 Figure 79: Figure 80: Global Molecular Diagnostics Market (Mycoplasma Infections), Thousand Units, 2020- 2031 Global Molecular Diagnostics Market (Pertussis), $Million, 2020-2031 Global Molecular Diagnostics Market (Pertussis), Thousand Units, 2020-2031 Global Molecular Diagnostics Market (Other Respiratory Infections), $Million, 2020-2031 Figure 81: Figure 82: Figure 83: Figure 84: Global Molecular Diagnostics Market (Other Respiratory Infections), Thousand Units, 2020-2031 Global Molecular Diagnostics Market (Hepatitis B), $Million, 2020-2031 Global Molecular Diagnostics Market (Hepatitis B), Thousand Units, 2020-2031 Global Molecular Diagnostics Market (HIV-AIDS), $Million, 2020-2031 Global Molecular Diagnostics Market (HIV-AIDS), Thousand Units, 2020-2031 Global Molecular Diagnostics Market (HPV), $Million, 2020-2031 Global Molecular Diagnostics Market (HPV), Thousand Units, 2020-2031 Global Molecular Diagnostics Market (Herpes Simplex Virus), $Million, 2020-2031 Figure 85: Figure 86: Figure 87: Figure 88: Figure 89: Figure 90: Figure 91: Figure 92: Global Molecular Diagnostics Market Global Molecular Diagnostics Market (Herpes Simplex Virus), Thousand Units, 2020- 2031 Global Molecular Diagnostics Market (Neisseria Gonorrhoeae), $Million, 2020-2031 Figure 93: Figure 94: Global Molecular Diagnostics Market (Neisseria Gonorrhoeae), Thousand Units, 2020- 2031 Global Molecular Diagnostics Market (Other STIs), $Million, 2020-2031 Global Molecular Diagnostics Market (Other STIs), Thousand Units, 2020-2031 Global Molecular Diagnostics Market (Hereditary Genetic Testing), $Million, 2020-2031 Figure 95: Figure 96: Figure 97: 18 All rights reserved at BIS Research Inc.

  19. Figure 98: Global Molecular Diagnostics Market (Hereditary Genetic Testing), Thousand Units, 2020-2031 Global Molecular Diagnostics Market (Blood Donor Screening), $Million, 2020-2031 Figure 99: Figure 100: Global Molecular Diagnostics Market (Blood Donor Screening), Thousand Units, 2020- 2031 Clinical Uses of Molecular Diagnostics in Cancer Global Molecular Diagnostics Market (Oncology), $Million, 2020-2031 Global Molecular Diagnostics Market (Oncology), Thousand Units, 2020-2031 Figure 101: Figure 102: Figure 103: Figure 104: Global Molecular Diagnostics Market (Human Leukocyte Antigen Testing), $Million, 2020-2031 Figure 105: Global Molecular Diagnostics Market (Human Leukocyte Antigen Testing), Thousand Units, 2020-2031 Figure 106: Global Molecular Diagnostics Market (Other Molecular Diagnostics Applications), $Million, 2020-2031 Figure 107: Global Molecular Diagnostics Market (Other Molecular Diagnostics Applications), Thousand Units, 2020-2031 Global Molecular Diagnostics Market (Reproductive Genetics), $Million, 2020-2031 Figure 108: Figure 109: Global Molecular Diagnostics Market (Reproductive Genetics), Thousand Units, 2020- 2031 Figure 110: Global Molecular Diagnostics Market (by Reproductive Genetics), $Million, 2020 and 2031 Global Molecular Diagnostics Market (Carrier Screening), $Million, 2020-2031 Global Molecular Diagnostics Market (Carrier Screening), Thousand Units, 2020-2031 Global Molecular Diagnostics Market (NIPT), $Million, 2020-2031 Global Molecular Diagnostics Market (NIPT), Thousand Units, 2020-2031 Figure 111: Figure 112: Figure 113: Figure 114: Figure 115: Global Molecular Diagnostics Market (Pre-Implantation Genetic Testing), $Million, 2020- 2031 Figure 116: Global Molecular Diagnostics Market (Pre-Implantation Genetic Testing), Thousand Units, 2020-2031 Global Molecular Diagnostics Market (Infertility Genetic Testing), $Million, 2020-2031 Figure 117: Figure 118: Global Molecular Diagnostics Market (Infertility Genetic Testing), Thousand Units, 2020- 2031 Global Molecular Diagnostics Market (Companion Diagnostics), $Million, 2020-2031 Figure 119: Figure 120: Global Molecular Diagnostics Market (Companion Diagnostics), Thousand Units, 2020- 2031 Global Molecular Diagnostics Market (Liquid Biopsy), $Million, 2020-2031 Global Molecular Diagnostics Market (Liquid Biopsy), Thousand Units, 2020-2031 Global Molecular Diagnostics Market (Other Applications), $Million, 2020-2031 Global Molecular Diagnostics Market (Other Applications), Thousand Units, 2020-2031 Share of Global Molecular Diagnostics Market (by End User), $Million, 2020 and 2031 Global Molecular Diagnostics Market Figure 121: Figure 122: Figure 123: Figure 124: Figure 125: Figure 126: Share of Global Molecular Diagnostics Market (by End User), Thousand Units, 2020 and 2031 Global Molecular Diagnostics Market (Hospitals), $Million, 2020-2031 Global Molecular Diagnostics Market (Hospitals), Thousand Units, 2020-2031 Figure 127: Figure 128: 19 All rights reserved at BIS Research Inc.

  20. Figure 129: Figure 130: Hospitals Molecular Diagnostics Market, Respiratory Infections, $Million, 2020-2031 Hospitals Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020- 2031 Hospitals Molecular Diagnostics Market, Influenza A and B, $Million, 2020-2031 Hospitals Molecular Diagnostics Market, Influenza A and B, Thousand Units, 2020-2031 Hospitals Molecular Diagnostics Market, COVID-19 Infections, $Million, 2020-2031 Figure 131: Figure 132: Figure 133: Figure 134: Hospitals Molecular Diagnostics Market, COVID-19 Infections, Thousand Units, 2020- 2031 Hospitals Molecular Diagnostics Market, Respiratory Syncytial Virus, $Million, 2020-2031 Figure 135: Figure 136: Hospitals Molecular Diagnostics Market, Respiratory Syncytial Virus, Thousand Units, 2020-2031 Hospitals Molecular Diagnostics Market, Mycoplasma Infection, $Million, 2020-2031 Figure 137: Figure 138: Hospitals Molecular Diagnostics Market, Mycoplasma Infection, Thousand Units, 2020- 2031 Hospitals Molecular Diagnostics Market, Pertussis, $Million, 2020-2031 Hospitals Molecular Diagnostics Market, Pertussis, Thousand Units, 2020-2031 Figure 139: Figure 140: Figure 141: Hospitals Molecular Diagnostics Market, Other Respiratory Infections, $Million, 2020- 2031 Figure 142: Hospitals Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031 Figure 143: Hospitals Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020- 2031 Figure 144: Hospitals Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031 Diagnostic Centers Molecular Diagnostics Market, Hepatitis B, $Million, 2020-2031 Hospitals Molecular Diagnostics Market, Hepatitis B, Thousand Units, 2020-2031 Diagnostic Centers Molecular Diagnostics Market, HIV AIDS, $Million, 2020-2031 Hospitals Molecular Diagnostics Market, HIV AIDS, Thousand Units, 2020-2031 Diagnostic Centers Molecular Diagnostics Market, HPV, $Million, 2020-2031 Hospitals Molecular Diagnostics Market, HPV, Thousand Units, 2020-2031 Diagnostic Centers Molecular Diagnostics Market, HSV, $Million, 2020-2031 Hospitals Molecular Diagnostics Market, HSV, Thousand Units, 2020-2031 Hospitals Molecular Diagnostics Market, Neisseria gonorrhoeae, $Million, 2020-2031 Figure 145: Figure 146: Figure 147: Figure 148: Figure 149: Figure 150: Figure 151: Figure 152: Figure 153: Figure 154: Global Molecular Diagnostics Market Hospitals Molecular Diagnostics Market, Neisseria gonorrhoeae, Thousand Units, 2020- 2031 Hospitals Molecular Diagnostics Market, Other STIs, $Million, 2020-2031 Hospitals Molecular Diagnostics Market, Other STIs, Thousand Units, 2020-2031 Global Molecular Diagnostics Market (Diagnostic Centers), $Million, 2020-2031 Global Molecular Diagnostics Market (Diagnostic Centers), Thousand Units, 2020-2031 Figure 155: Figure 156: Figure 157: Figure 158: Figure 159: Diagnostic Centers Molecular Diagnostics Market, Respiratory Infections, $Million, 2020- 2031 Figure 160: Diagnostic Centers Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020-2031 20 All rights reserved at BIS Research Inc.

  21. Figure 161: Diagnostic Centers Molecular Diagnostics Market, Influenza A and B, $Million, 2020- 2031 Figure 162: Diagnostic Centers Molecular Diagnostics Market, Influenza A and B, Thousand Units, 2020-2031 Figure 163: Diagnostic Centers Molecular Diagnostics Market, COVID-19 Infections, $Million, 2020- 2031 Figure 164: Diagnostic Centers Molecular Diagnostics Market, COVID-19 Infections, Thousand Units, 2020-2031 Figure 165: Diagnostic Centers Molecular Diagnostics Market, Respiratory Syncytial Virus, $Million, 2020-2031 Figure 166: Diagnostic Centers Molecular Diagnostics Market, Respiratory Syncytial Virus, Thousand Units, 2020-2031 Figure 167: Diagnostic Centers Molecular Diagnostics Market, Mycoplasma Infection, $Million, 2020- 2031 Figure 168: Diagnostic Centers Molecular Diagnostics Market, Mycoplasma Infection, Thousand Units, 2020-2031 Diagnostic Centers Molecular Diagnostics Market, Pertussis, $Million, 2020-2031 Figure 169: Figure 170: Diagnostic Centers Molecular Diagnostics Market, Pertussis, Thousand Units, 2020- 2031 Figure 171: Diagnostic Centers Molecular Diagnostics Market, Other Respiratory Infections, $Million, 2020-2031 Figure 172: Diagnostic Centers Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031 Figure 173: Diagnostic Centers Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020-2031 Figure 174: Diagnostic Centers Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031 Diagnostic Centers Molecular Diagnostics Market, Hepatitis B, $Million, 2020-2031 Figure 175: Figure 176: Diagnostic Centers Molecular Diagnostics Market, Hepatitis B, Thousand Units, 2020- 2031 Diagnostic Centers Molecular Diagnostics Market, HIV AIDS, $Million, 2020-2031 Figure 177: Figure 178: Diagnostic Centers Molecular Diagnostics Market, HIV AIDS, Thousand Units, 2020- 2031 Diagnostic Centers Molecular Diagnostics Market, HPV, $Million, 2020-2031 Diagnostic Centers Molecular Diagnostics Market, HPV, Thousand Units, 2020-2031 Diagnostic Centers Molecular Diagnostics Market, HSV, $Million, 2020-2031 Diagnostic Centers Molecular Diagnostics Market, HSV, Thousand Units, 2020-2031 Figure 179: Figure 180: Figure 181: Figure 182: Figure 183: Global Molecular Diagnostics Market Diagnostic Centers Molecular Diagnostics Market, Neisseria gonorrhoeae, $Million, 2020-2031 Figure 184: Diagnostic Centers Molecular Diagnostics Market, Neisseria gonorrhoeae, Thousand Units, 2020-2031 Diagnostic Centers Molecular Diagnostics Market, Other STIs, $Million, 2020-2031 Figure 185: Figure 186: Diagnostic Centers Molecular Diagnostics Market, Other STIs, Thousand Units, 2020- 2031 Figure 187: Global Molecular Diagnostics Market (Out-Patient Clinics/General Practitioners), $Million, 2020-2031 21 All rights reserved at BIS Research Inc.

  22. Figure 188: Global Molecular Diagnostics Market (Out-Patient Clinics/General Practitioners), Thousand Units, 2020-2031 Figure 189: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Respiratory Infections, $Million, 2020-2031 Figure 190: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020-2031 Figure 191: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Influenza A and B, $Million, 2020-2031 Figure 192: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Influenza A and B, Thousand Units, 2020-2031 Figure 193: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, COVID-19 Infections, $Million, 2020-2031 Figure 194: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, COVID-19 Infections, Thousand Units, 2020-2031 Figure 195: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Respiratory Syncytial Virus, $Million, 2020-2031 Figure 196: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Respiratory Syncytial Virus, Thousand Units, 2020-2031 Figure 197: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Mycoplasma Infection, $Million, 2020-2031 Figure 198: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Mycoplasma Infection, Thousand Units, 2020-2031 Diagnostic Centers Molecular Diagnostics Market, Pertussis, $Million, 2020-2031 Figure 199: Figure 200: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Pertussis, Thousand Units, 2020-2031 Figure 201: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Other Respiratory Infections, $Million, 2020-2031 Figure 202: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031 Figure 203: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020-2031 Figure 204: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031 Figure 205: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Hepatitis B, $Million, 2020-2031 Figure 206: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Hepatitis B, Thousand Units, 2020-2031 Diagnostic Centers Molecular Diagnostics Market, HIV AIDS, $Million, 2020-2031 Global Molecular Diagnostics Market Figure 207: Figure 208: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, HIV AIDS, Thousand Units, 2020-2031 Diagnostic Centers Molecular Diagnostics Market, HPV, $Million, 2020-2031 Figure 209: Figure 210: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, HPV, Thousand Units, 2020-2031 Figure 211: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, HSV, $Million, 2020-2031 Figure 212: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, HSV, Thousand Units, 2020-2031 22 All rights reserved at BIS Research Inc.

  23. Figure 213: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Neisseria gonorrhoeae, $Million, 2020-2031 Figure 214: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Neisseria gonorrhoeae, Thousand Units, 2020-2031 Figure 215: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Other STIs, $Million, 2020-2031 Figure 216: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Other STIs, Thousand Units, 2020-2031 Global Molecular Diagnostics Market (Research Laboratories), $Million, 2020-2031 Figure 217: Figure 218: Global Molecular Diagnostics Market (Research Laboratories), Thousand Units, 2020- 2031 Figure 219: Research Laboratories Molecular Diagnostics Market, Respiratory Infections, $Million, 2020-2031 Figure 220: Research Laboratories Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020-2031 Figure 221: Research Laboratories Molecular Diagnostics Market, Influenza A and B, $Million, 2020- 2031 Figure 222: Research Laboratories Molecular Diagnostics Market, Influenza A and B, Thousand Units, 2020-2031 Figure 223: Research Laboratories Molecular Diagnostics Market, COVID-19 Infections, $Million, 2020-2031 Figure 224: Research Laboratories Molecular Diagnostics Market, COVID-19 Infections, Thousand Units, 2020-2031 Figure 225: Research Laboratories Molecular Diagnostics Market, Respiratory Syncytial Virus, $Million, 2020-2031 Figure 226: Research Laboratories Molecular Diagnostics Market, Respiratory Syncytial Virus, Thousand Units, 2020-2031 Figure 227: Research Laboratories Molecular Diagnostics Market, Mycoplasma Infection, $Million, 2020-2031 Figure 228: Research Laboratories Molecular Diagnostics Market, Mycoplasma Infection, Thousand Units, 2020-2031 Research Laboratories Molecular Diagnostics Market, Pertussis, $Million, 2020-2031 Figure 229: Figure 230: Research Laboratories Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031 Figure 231: Research Laboratories Molecular Diagnostics Market, Other Respiratory Infections, $Million, 2020-2031 Global Molecular Diagnostics Market Figure 232: Research Laboratories Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031 Figure 233: Research Laboratories Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020-2031 Figure 234: Research Laboratories Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031 Research Laboratories Molecular Diagnostics Market, Hepatitis B, $Million, 2020-2031 Figure 235: Figure 236: Research Laboratories Molecular Diagnostics Market, Hepatitis B, Thousand Units, 2020-2031 Research Laboratories Molecular Diagnostics Market, HIV AIDS, $Million, 2020-2031 Figure 237: 23 All rights reserved at BIS Research Inc.

  24. Figure 238: Research Laboratories Molecular Diagnostics Market, HIV AIDS, Thousand Units, 2020- 2031 Research Laboratories Molecular Diagnostics Market, HPV, $Million, 2020-2031 Research Laboratories Molecular Diagnostics Market, HPV, Thousand Units, 2020-2031 Research Laboratories Molecular Diagnostics Market, HSV, $Million, 2020-2031 Research Laboratories Molecular Diagnostics Market, HSV, Thousand Units, 2020-2031 Figure 239: Figure 240: Figure 241: Figure 242: Figure 243: Research Laboratories Molecular Diagnostics Market, Neisseria gonorrhoeae, $Million, 2020-2031 Figure 244: Research Laboratories Molecular Diagnostics Market, Neisseria gonorrhoeae, Thousand Units, 2020-2031 Research Laboratories Molecular Diagnostics Market, Other STIs, $Million, 2020-2031 Figure 245: Figure 246: Research Laboratories Molecular Diagnostics Market, Other STIs, Thousand Units, 2020-2031 Global Molecular Diagnostics Market (Other End Users), $Million, 2020-2031 Global Molecular Diagnostics Market (Other End Users), Thousand Units, 2020-2031 Global Molecular Diagnostics Market (by Region), $Million, 2020-2031 Figure 247: Figure 248: Figure 249: Figure 250: Share of North America Molecular Diagnostics Market Revenue (by Country), $Million, 2020 and 2031 North America Molecular Diagnostics Market, $Million, 2020-2031 North America Molecular Diagnostics Market, Thousand Units, 2020-2031 North America: Market Dynamics North America Molecular Diagnostics Market (by Application), $Million, 2020 and 2031 North America Molecular Diagnostics Market, Respiratory Infections, $Million, 2020-2031 Figure 251: Figure 252: Figure 253: Figure 254: Figure 255: Figure 256: North America Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020-2031 North America Molecular Diagnostics Market, Influenza A and B, $Million, 2020-2031 Figure 257: Figure 258: North America Molecular Diagnostics Market, Influenza A and B, Thousand Units, 2020- 2031 North America Molecular Diagnostics Market, COVID-19 Infections, $Million, 2020-2031 Figure 259: Figure 260: North America Molecular Diagnostics Market, COVID-19 Infections, Thousand Units, 2020-2031 Figure 261: North America Molecular Diagnostics Market, Respiratory Syncytial Virus, $Million, 2020- 2031 Global Molecular Diagnostics Market Figure 262: North America Molecular Diagnostics Market, Respiratory Syncytial Virus, Thousand Units, 2020-2031 North America Molecular Diagnostics Market, Mycoplasma Infection, $Million, 2020-2031 Figure 263: Figure 264: North America Molecular Diagnostics Market, Mycoplasma Infection, Thousand Units, 2020-2031 North America Molecular Diagnostics Market, Pertussis, $Million, 2020-2031 North America Molecular Diagnostics Market, Pertussis, Thousand Units, 2020-2031 Figure 265: Figure 266: Figure 267: North America Molecular Diagnostics Market, Other Respiratory Infections, $Million, 2020-2031 Figure 268: North America Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031 24 All rights reserved at BIS Research Inc.

  25. Figure 269: North America Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020-2031 Figure 270: North America Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031 North America Molecular Diagnostics Market, Hepatitis B, $Million, 2020-2031 North America Molecular Diagnostics Market, Hepatitis B, Thousand Units, 2020-2031 North America Molecular Diagnostics Market, HIV AIDS, $Million, 2020-2031 North America Molecular Diagnostics Market, HIV AIDS, Thousand Units, 2020-2031 North America Molecular Diagnostics Market, HPV, $Million, 2020-2031 North America Molecular Diagnostics Market, HPV, Thousand Units, 2020-2031 North America Molecular Diagnostics Market, HSV, $Million, 2020-2031 North America Molecular Diagnostics Market, HSV, Thousand Units, 2020-2031 Figure 271: Figure 272: Figure 273: Figure 274: Figure 275: Figure 276: Figure 277: Figure 278: Figure 279: North America Molecular Diagnostics Market, Neisseria gonorrhoeae, $Million, 2020- 2031 Figure 280: North America Molecular Diagnostics Market, Neisseria gonorrhoeae, Thousand Units, 2020-2031 North America Molecular Diagnostics Market, Other STIs, $Million, 2020-2031 North America Molecular Diagnostics Market, Other STIs, Thousand Units, 2020-2031 North America Molecular Diagnostics Market (by End User), $Million, 2020 and 2031 U.S. Molecular Diagnostics Market, $Million, 2020-2031 U.S. Molecular Diagnostics Market, Thousand Units, 2020-2031 Canada Molecular Diagnostics Market, $Million, 2020-2031 Canada Molecular Diagnostics Market, Thousand Units, 2020-2031 Europe Molecular Diagnostics Market (by Country), $Million, 2020 and 2031 Europe Molecular Diagnostics Market, $Million, 2020-2031 Europe Molecular Diagnostics Market, Thousand Units, 2020-2031 Europe: Market Dynamics Europe Molecular Diagnostics Market (by Application), $Million Europe Molecular Diagnostics Market, Respiratory Infections, $Million, 2020-2031 Figure 281: Figure 282: Figure 283: Figure 284: Figure 285: Figure 286: Figure 287: Figure 288: Figure 289: Figure 290: Figure 291: Figure 292: Figure 293: Figure 294: Europe Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020- 2031 Europe Molecular Diagnostics Market, Influenza A and B, $Million, 2020-2031 Europe Molecular Diagnostics Market, Influenza A and B, Thousand Units, 2020-2031 Europe Molecular Diagnostics Market, COVID-19 Infections, $Million, 2020-2031 Europe Molecular Diagnostics Market, COVID-19 Infections, Thousand Units, 2020-2031 Europe Molecular Diagnostics Market, Respiratory Syncytial Virus, $Million, 2020-2031 Figure 295: Figure 296: Figure 297: Figure 298: Figure 299: Figure 300: Global Molecular Diagnostics Market Europe Molecular Diagnostics Market, Respiratory Syncytial Virus, Thousand Units, 2020-2031 Europe Molecular Diagnostics Market, Mycoplasma Infection, $Million, 2020-2031 Figure 301: Figure 302: Europe Molecular Diagnostics Market, Mycoplasma Infection, Thousand Units, 2020- 2031 Europe Molecular Diagnostics Market, Pertussis, $Million, 2020-2031 Figure 303: 25 All rights reserved at BIS Research Inc.

  26. Figure 304: Figure 305: Figure 306: Europe Molecular Diagnostics Market, Pertussis, Thousand Units, 2020-2031 Europe Molecular Diagnostics Market, Other Respiratory Infections, $Million, 2020-2031 Europe Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031 Figure 307: Europe Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020- 2031 Figure 308: Europe Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031 Europe Molecular Diagnostics Market, Hepatitis B, $Million, 2020-2031 Europe Molecular Diagnostics Market, Hepatitis B, Thousand Units, 2020-2031 Europe Molecular Diagnostics Market, HIV AIDS, $Million, 2020-2031 Europe Molecular Diagnostics Market, HIV AIDS, Thousand Units, 2020-2031 Europe Molecular Diagnostics Market, HPV, $Million, 2020-2031 Europe Molecular Diagnostics Market, HPV, Thousand Units, 2020-2031 Europe Molecular Diagnostics Market, HSV, $Million, 2020-2031 Europe Molecular Diagnostics Market, HSV, Thousand Units, 2020-2031 Europe Molecular Diagnostics Market, Neisseria gonorrhoeae, $Million, 2020-2031 Figure 309: Figure 310: Figure 311: Figure 312: Figure 313: Figure 314: Figure 315: Figure 316: Figure 317: Figure 318: Europe Molecular Diagnostics Market, Neisseria gonorrhoeae, Thousand Units, 2020- 2031 Europe Molecular Diagnostics Market, Other STIs, $Million, 2020-2031 Europe Molecular Diagnostics Market, Other STIs, Thousand Units, 2020-2031 Europe Molecular Diagnostics Market (by End User), $Million, 2020 and 2031 Germany Molecular Diagnostics Market, $Million, 2020-2031 Germany Molecular Diagnostics Market, Thousand Units, 2020-2031 U.K. Molecular Diagnostics Market, $Million, 2020-2031 U.K. Molecular Diagnostics Market, Thousand Units, 2020-2031 France Molecular Diagnostics Market, $Million, 2020-2031 France Molecular Diagnostics Market, Thousand Units, 2020-2031 Italy Molecular Diagnostics Market, $Million, 2020-2031 Italy Molecular Diagnostics Market, Thousand Units, 2020-2031 Spain Molecular Diagnostics Market, $Million, 2020-2031 Spain Molecular Diagnostics Market, Thousand Units, 2020-2031 Rest-of-Europe Molecular Diagnostics Market, $Million, 2020-2031 Rest-of-Europe Molecular Diagnostics Market, Thousand Units, 2020-2031 Asia-Pacific Molecular Diagnostics Market (by Country), $Million, 2020 and 2031 Asia-Pacific Molecular Diagnostics Market, $Million, 2020-2031 Asia-Pacific Molecular Diagnostics Market, Thousand Units, 2020-2031 Asia-Pacific: Market Dynamics Asia-Pacific Molecular Diagnostics Market (by Application), $Million, 2020 and 2031 Asia-Pacific Molecular Diagnostics Market, Respiratory Infections, $Million, 2020-2031 Figure 319: Figure 320: Figure 321: Figure 322: Figure 323: Figure 324: Figure 325: Figure 326: Figure 327: Figure 328: Figure 329: Figure 330: Figure 331: Figure 332: Figure 333: Figure 334: Figure 335: Figure 336: Figure 337: Figure 338: Figure 339: Global Molecular Diagnostics Market 26 All rights reserved at BIS Research Inc.

  27. Figure 340: Asia-Pacific Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020-2031 Asia-Pacific Molecular Diagnostics Market, Influenza A and B, $Million, 2020-2031 Figure 341: Figure 342: Asia-Pacific Molecular Diagnostics Market, Influenza A and B, Thousand Units, 2020- 2031 Asia-Pacific Molecular Diagnostics Market, COVID-19 Infections, $Million, 2020-2031 Figure 343: Figure 344: Asia-Pacific Molecular Diagnostics Market, COVID-19 Infections, Thousand Units, 2020- 2031 Figure 345: Asia-Pacific Molecular Diagnostics Market, Respiratory Syncytial Virus, $Million, 2020- 2031 Figure 346: Asia-Pacific Molecular Diagnostics Market, Respiratory Syncytial Virus, Thousand Units, 2020-2031 Asia-Pacific Molecular Diagnostics Market, Mycoplasma Infection, $Million, 2020-2031 Figure 347: Figure 348: Asia-Pacific Molecular Diagnostics Market, Mycoplasma Infection, Thousand Units, 2020-2031 Asia-Pacific Molecular Diagnostics Market, Pertussis, $Million, 2020-2031 Asia-Pacific Molecular Diagnostics Market, Pertussis, Thousand Units, 2020-2031 Figure 349: Figure 350: Figure 351: Asia-Pacific Molecular Diagnostics Market, Other Respiratory Infections, $Million, 2020- 2031 Figure 352: Asia-Pacific Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031 Figure 353: Asia-Pacific Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020-2031 Figure 354: Asia-Pacific Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031 Asia-Pacific Molecular Diagnostics Market, Hepatitis B, $Million, 2020-2031 Asia-Pacific Molecular Diagnostics Market, Hepatitis B, Thousand Units, 2020-2031 Asia-Pacific Molecular Diagnostics Market, HIV AIDS, $Million, 2020-2031 Asia-Pacific Molecular Diagnostics Market, HIV AIDS, Thousand Units, 2020-2031 Asia-Pacific Molecular Diagnostics Market, HPV, $Million, 2020-2031 Asia-Pacific Molecular Diagnostics Market, HPV, Thousand Units, 2020-2031 Asia-Pacific Molecular Diagnostics Market, HSV, $Million, 2020-2031 Asia-Pacific Molecular Diagnostics Market, HSV, Thousand Units, 2020-2031 Asia-Pacific Molecular Diagnostics Market, Neisseria gonorrhoeae, $Million, 2020-2031 Figure 355: Figure 356: Figure 357: Figure 358: Figure 359: Figure 360: Figure 361: Figure 362: Figure 363: Figure 364: Global Molecular Diagnostics Market Asia-Pacific Molecular Diagnostics Market, Neisseria gonorrhoeae, Thousand Units, 2020-2031 Asia-Pacific Molecular Diagnostics Market, Other STIs, $Million, 2020-2031 Asia-Pacific Molecular Diagnostics Market, Other STIs, Thousand Units, 2020-2031 Asia-Pacific Molecular Diagnostics Market (by End User), $Million, 2020 and 2031 China Molecular Diagnostics Market, $Million, 2020-2031 China Molecular Diagnostics Market, Thousand Units, 2020-2031 India Molecular Diagnostics Market, $Million, 2020-2031 India Molecular Diagnostics Market, Thousand Units, 2020-2031 Figure 365: Figure 366: Figure 367: Figure 368: Figure 369: Figure 370: Figure 371: 27 All rights reserved at BIS Research Inc.

  28. Figure 372: Figure 373: Figure 374: Figure 375: Figure 376: Figure 377: Figure 378: Figure 379: Figure 380: Figure 381: Figure 382: Figure 383: Figure 384: Figure 385: Figure 386: Japan Molecular Diagnostics Market, $Million, 2020-2031 Japan Molecular Diagnostics Market, Thousand Units, 2020-2031 Australia Molecular Diagnostics Market, $Million, 2020-2031 Australia Molecular Diagnostics Market, Thousand Units, 2020-2031 Singapore Molecular Diagnostics Market, $Million, 2020-2031 Singapore Molecular Diagnostics Market, Thousand Units, 2020-2031 Rest-of-Asia-Pacific Molecular Diagnostics Market, $Million, 2020-2031 Rest-of-Asia-Pacific Molecular Diagnostics Market, Thousand Units, 2020-2031 Latin America Molecular Diagnostics Market (by Country), $Million 2020-2031 Latin America Molecular Diagnostics Market, $Million, 2020-2031 Latin America Molecular Diagnostics Market, Thousand Units, 2020-2031 LATAM: Market Dynamics Latin America Molecular Diagnostics Market (by Application), $Million, 2020 and 2031 Latin America Molecular Diagnostics Market, Respiratory Infections, $Million, 2020-2031 Latin America Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020-2031 Latin America Molecular Diagnostics Market, Influenza A and B, $Million, 2020-2031 Figure 387: Figure 388: Latin America Molecular Diagnostics Market, Influenza A and B, Thousand Units, 2020- 2031 Latin America Molecular Diagnostics Market, COVID-19 Infections, $Million, 2020-2031 Figure 389: Figure 390: Latin America Molecular Diagnostics Market, COVID-19 Infections, Thousand Units, 2020-2031 Figure 391: Latin America Molecular Diagnostics Market, Respiratory Syncytial Virus, $Million, 2020- 2031 Figure 392: Latin America Molecular Diagnostics Market, Respiratory Syncytial Virus, Thousand Units, 2020-2031 Latin America Molecular Diagnostics Market, Mycoplasma Infection, $Million, 2020-2031 Figure 393: Figure 394: Latin America Molecular Diagnostics Market, Mycoplasma Infection, Thousand Units, 2020-2031 Latin America Molecular Diagnostics Market, Pertussis, $Million, 2020-2031 Latin America Molecular Diagnostics Market, Pertussis, Thousand Units, 2020-2031 Figure 395: Figure 396: Figure 397: Latin America Molecular Diagnostics Market, Other Respiratory Infections, $Million, 2020-2031 Global Molecular Diagnostics Market Figure 398: Latin America Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031 Figure 399: Latin America Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020-2031 Figure 400: Latin America Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031 Latin America Molecular Diagnostics Market, Hepatitis B, $Million, 2020-2031 Latin America Molecular Diagnostics Market, Hepatitis B, Thousand Units, 2020-2031 Latin America Molecular Diagnostics Market, HIV AIDS, $Million, 2020-2031 Latin America Molecular Diagnostics Market, HIV AIDS, Thousand Units, 2020-2031 Figure 401: Figure 402: Figure 403: Figure 404: 28 All rights reserved at BIS Research Inc.

  29. Figure 405: Figure 406: Figure 407: Figure 408: Figure 409: Latin America Molecular Diagnostics Market, HPV, $Million, 2020-2031 Latin America Molecular Diagnostics Market, HPV, Thousand Units, 2020-2031 Latin America Molecular Diagnostics Market, HSV, $Million, 2020-2031 Latin America Molecular Diagnostics Market, HSV, Thousand Units, 2020-2031 Latin America Molecular Diagnostics Market, Neisseria gonorrhoeae, $Million, 2020- 2031 Figure 410: Latin America Molecular Diagnostics Market, Neisseria gonorrhoeae, Thousand Units, 2020-2031 Latin America Molecular Diagnostics Market, Other STIs, $Million, 2020-2031 Latin America Molecular Diagnostics Market, Other STIs, Thousand Units, 2020-2031 Latin America Molecular Diagnostics Market (by End User), $Million, 2020 and 2031 Brazil Molecular Diagnostics Market, $Million, 2020-2031 Brazil Molecular Diagnostics Market, Thousand Units, 2020-2031 Mexico Molecular Diagnostics Market, $Million, 2020-2031 Mexico Molecular Diagnostics Market, Thousand Units, 2020-2031 Rest-of-Latin America Molecular Diagnostics Market, $Million, 2020-2031 Rest-of-Asia-Pacific Molecular Diagnostics Market, Thousand Units, 2020-2031 Rest-of-the-World Molecular Diagnostics Market, $Million, 2020-2031 Rest-of-the-World Molecular Diagnostics Market, Thousand Units, 2020-2031 Figure 411: Figure 412: Figure 413: Figure 414: Figure 415: Figure 416: Figure 417: Figure 418: Figure 419: Figure 420: Figure 421: Figure 422: Rest-of-the-World Molecular Diagnostics Market (by Application), $Million, 2020 and 2031 Rest-of-the-World Molecular Diagnostics Market (by End User), $Million, 2020 and 2031 Figure 423: Figure 424: Rest-of-the-World Molecular Diagnostics Market, Respiratory Infections, $Million, 2020- 2031 Figure 425: Rest-of-the-World Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020-2031 Share of Rest-of-the-World Market (by Respiratory Infections), $Million, 2020 and 2031 Figure 426: Figure 427: Rest-of-the-World Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020-2031 Figure 428: Rest-of-the-World Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031 Figure 429: Share of Rest-of-the-World Market (by Sexually Transmitted Infections), $Million, 2020 and 2031 Share of Key Companies Profiled Abbott: Overall Product Portfolio Abbott: Overall Financials, 2018-2020 Abbott: Revenue (by Segment), 2018-2020 Abbott: Revenue (by Region), 2018-2020 Abbott: R&D Expenditure, 2018-2020 Abbott: SWOT Analysis Agilent Technologies, Inc.: Overall Product Portfolio Agilent Technologies, Inc.: Overall Financials, 2018-2020 Global Molecular Diagnostics Market Figure 430: Figure 431: Figure 432: Figure 433: Figure 434: Figure 435: Figure 436: Figure 437: Figure 438: 29 All rights reserved at BIS Research Inc.

  30. Figure 439: Figure 440: Figure 441: Figure 442: Figure 443: Figure 444: Figure 445: Figure 446: Figure 447: Figure 448: Figure 449: Figure 450: Figure 451: Figure 452: Figure 453: Figure 454: Figure 455: Figure 456: Figure 457: Figure 458: Figure 459: Figure 460: Figure 461: Figure 462: Figure 463: Figure 464: Figure 465: Figure 466: Figure 467: Figure 468: Figure 469: Figure 470: Figure 471: Figure 472: Figure 473: Figure 474: Figure 475: Figure 476: Figure 477: Agilent Technologies, Inc.: Revenue (by Segment), 2018-2020 Agilent Technologies, Inc.: Revenue (by Region), 2018-2020 Agilent Technologies, Inc.: R&D Expenditure, 2018-2020 Agilent Technologies, Inc.: SWOT Analysis Becton, Dickinson and Company (BD): Overall Product Portfolio Becton, Dickinson and Company (BD): Overall Financials, 2018-2020 Becton, Dickinson and Company (BD): Revenue (by Segment), 2018-2020 Becton, Dickinson and Company (BD): Revenue (by Region), 2018-2020 Becton, Dickinson and Company (BD): R&D Expenditure, 2018-2020 Becton, Dickinson and Company: SWOT Analysis bioMérieux SA: Overall Product Portfolio bioMérieux SA: Overall Financials, 2018-2020 bioMérieux SA: Revenue (by Segment), 2018-2020 bioMérieux SA: Revenue (by Region), 2018-2020 bioMérieux SA: R&D Expenditure, 2018-2020 bioMérieux SA: SWOT Analysis Bio-Rad Laboratories, Inc.: Overall Product Portfolio Bio-Rad Laboratories, Inc.: Overall Financials, 2018-2020 Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2018-2020 Bio-Rad Laboratories, Inc.: Revenue (by Region), 2018-2020 Bio-Rad Laboratories, Inc.: R&D Expenditure, 2018-2020 Bio-Rad Laboratories, Inc.: SWOT Analysis Danaher: Overall Product Portfolio Danaher: Overall Financials, 2018-2020 Danaher: Revenue (by Segment), 2018-2020 Danaher: Revenue (by Region), 2018-2020 Danaher: R&D Expenditure, 2018-2020 Danaher: SWOT Analysis F. Hoffmann-La Roche Ltd: Overall Product Portfolio F. Hoffmann-La Roche Ltd: Overall Financials, 2018-2020 F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2018-2020 F. Hoffmann-La Roche Ltd: Revenue (by Region), 2018-2020 F. Hoffmann-La Roche Ltd: R&D Expenditure, 2018-2020 F. Hoffmann-La Roche Ltd: SWOT Analysis Guardant Health: Overall Product Portfolio Guardant Health: Overall Financials, 2018-2020 Guardant Health: Revenue (by Segment), 2018-2020 Guardant Health: R&D Expenditure, 2018-2020 Guardant Health: SWOT Analysis Global Molecular Diagnostics Market 30 All rights reserved at BIS Research Inc.

  31. Figure 478: Figure 479: Figure 480: Figure 481: Figure 482: Figure 483: Figure 484: Figure 485: Figure 486: Figure 487: Figure 488: Figure 489: Figure 490: Figure 491: Figure 492: Figure 493: Figure 494: Figure 495: Figure 496: Figure 497: Figure 498: Figure 499: Figure 500: Figure 501: Figure 502: Figure 503: Figure 504: Figure 505: Figure 506: Figure 507: Figure 508: Figure 509: Figure 510: Figure 511: Figure 512: Figure 513: Figure 514: HTG Molecular Diagnostics, Inc.: Overall Product Portfolio HTG Molecular Diagnostics, Inc.: Overall Financials, 2018-2020 HTG Molecular Diagnostics, Inc.: Revenue (by Segment), 2018-2020 HTG Molecular Diagnostics, Inc.: R&D Expenditure, 2018-2020 HTG Molecular Diagnostics, Inc.: SWOT Analysis Illumina, Inc.: Overall Product Portfolio Illumina, Inc.: Overall Financials, 2018-2020 Illumina, Inc.: Revenue (by Segment), 2018-2020 Illumina, Inc.: Revenue (by Region), 2018-2020 Illumina, Inc.: R&D Expenditure, 2018-2020 Illumina, Inc.: SWOT Analysis Invivoscribe, Inc.: Overall Product Portfolio Invivoscribe, Inc.: SWOT Analysis ICON plc: Overall Product Portfolio ICON plc: SWOT Analysis LungLife AI, Inc.: Overall Product Portfolio LungLife AI, Inc.: SWOT Analysis QIAGEN: Overall Product Portfolio QIAGEN: Overall Financials, 2018-2020 QIAGEN: Revenue (by Segment), 2018-2020 QIAGEN: Revenue (by Region), 2018-2020 QIAGEN: R&D Expenditure, 2018-2020 QIAGEN: SWOT Analysis QuantuMDx Group Ltd.: Overall Product Portfolio QuantuMDx Group Ltd.: SWOT Analysis Siemens Healthcare GmbH: Overall Product Portfolio Siemens Healthcare GmbH: Overall Financials, 2018-2020 Siemens Healthcare GmbH: Revenue (by Segment), 2018-2020 Siemens Healthcare GmbH: Revenue (by Region), 2018-2020 Siemens Healthcare GmbH: R&D Expenditure, 2018-2020 Siemens Healthcare GmbH: SWOT Analysis Thermo Fisher Scientific Inc.: Overall Product Portfolio Thermo Fisher Scientific Inc.: Overall Financials, 2018-2020 Thermo Fisher Scientific Inc.: Revenue (by Segment), 2018-2020 Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020 Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020 Thermo Fisher Scientific Inc.: SWOT Analysis Global Molecular Diagnostics Market 31 All rights reserved at BIS Research Inc.

  32. List of Tables Table 1: Table 2: Table 3: Table 4: Table 5: Table 6: Table 7: Table 8: Biomarkers for Various Diseases FDA-Approved Drugs with a Companion Diagnostic COVID-19 Impact on Global Molecular Diagnostics Market Products Launched by Various Manufacturers for Molecular Diagnostics Research Registration Criteria for IVD Medical Devices as per the CFDA Approved Next-Generation Sequencing (NGS) Panels in Japan Pathogens Responsible for Different Respiratory Infections Key Biomarker Testing Products for Respiratory Infections Offered by Major Market Players Genetic Tests for Certain Applications Examples of Molecular Diagnostics in Cancer Table 9: Table 10: Table 11: North America Molecular Diagnostics Market (by End User), Thousand Units, 2020, 2025, and 2031 Table 12: Europe Molecular Diagnostics Market (by Application), Thousand Units, 2020, 2025, and 2031 Table 13: Europe Molecular Diagnostics Market (by End User), Thousand Units, 2020,2025 and 2031 Table 14: Asia-Pacific Molecular Diagnostics Market (by Application), Thousand Units, 2020, 2025, and 2031 Table 15: Asia-Pacific Molecular Diagnostics Market (by End User), Thousand Units, 2020, 2025, and 2031 Table 16: Latin America Molecular Diagnostics Market (by Application), Thousand Units, 2020, 2025, and 2031 Table 17: Latin America Molecular Diagnostics Market (by End User), Thousand Units, 2020, 2025, and 2031 Table 18: Rest-of-the-World Molecular Diagnostics Market (by Application), Thousand Units, 2020, 2025, and 2031 Table 19: Rest-of-the-World Molecular Diagnostics Market (by End User), Thousand Units, 2020, 2025, and 2031 Global Molecular Diagnostics Market 32 All rights reserved at BIS Research Inc.

  33. BIS Research Offerings: We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s digital age. We have a vision to be a leading and a preferred knowledge partner for corporates and institutions worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other innovative solutions. Know More Know More Know More Global Molecular Diagnostics Market Know More 33 All rights reserved at BIS Research Inc.

  34. Disclaimer BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth. This document and its contents are confidential and may not be further distributed, published or reproduced, in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce Information in legal proceedings. Market reports are based on expectations, estimates and projections as of the date such information is available. Any recommendation contained in this report may not be suitable for all investors or businesses. The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to market fluctuations and business, economic and competitive uncertainties and contingencies. For more details regarding permission, please contact us: Email: sales@bisresearch.com Tel: +1 510 404 8135 Global Molecular Diagnostics Market 34 All rights reserved at BIS Research Inc.

  35. BIS RESEARCH INC. 39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686 Global Molecular Diagnostics Market E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135 Global Delivery Center Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway, Sector 126, Noida, U.P., 201303, India Tel: +91 120 4261540 / 4261544 35 www.bisresearch.com All rights reserved at BIS Research Inc.

More Related